Sandbox:Hannan1: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
Line 398: | Line 398: | ||
* | * | ||
|- | |- | ||
| | | colspan="2" |Jejuno-Ileal neuroendocrine tumors | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | colspan="2" |Appendix neuroendocrine tumors | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | colspan="2" |Colon neuroendocrine tumors | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | colspan="2" |Rectum neuroendocrine tumors | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan=" | | rowspan="4" |Gastric neuroendocrine tumors | ||
| | |Type I GNET | ||
| | | | ||
| | | | ||
Line 617: | Line 459: | ||
| | | | ||
|- | |- | ||
| | |Type II GNET | ||
| | | | ||
| | | | ||
Line 629: | Line 471: | ||
| | | | ||
|- | |- | ||
| | |Type III GNET | ||
| | | | ||
| | | | ||
Line 641: | Line 483: | ||
| | | | ||
|- | |- | ||
| | |Type IV GNET | ||
| | | | ||
| | | | ||
Line 653: | Line 495: | ||
| | | | ||
|- | |- | ||
| | | rowspan="5" |Duodenal neuroendocrine tumors | ||
|Gastrinoma | |||
| | | | ||
| | | | ||
Line 665: | Line 508: | ||
| | | | ||
|- | |- | ||
| | |Somatostatinomas | ||
| | | | ||
| | | | ||
Line 677: | Line 520: | ||
| | | | ||
|- | |- | ||
| | |Gangliocytic paraganglionomas | ||
| | | | ||
| | | | ||
Line 690: | Line 532: | ||
| | | | ||
|- | |- | ||
| | |Nonfunctioning NET | ||
| | | | ||
| | | | ||
Line 702: | Line 544: | ||
| | | | ||
|- | |- | ||
| | |neuroendocrine carcinomas | ||
| | | | ||
| | | | ||
Line 714: | Line 556: | ||
| | | | ||
|- | |- | ||
| | | rowspan="6" |Pancreatic neuroendocrine tumours | ||
|Gastrinoma | |||
| | | | ||
| | | | ||
Line 726: | Line 569: | ||
| | | | ||
|- | |- | ||
| | |Insulinoma | ||
| | | | ||
| | | | ||
Line 739: | Line 581: | ||
| | | | ||
|- | |- | ||
| | |Glucagonoma | ||
| | | | ||
| | | | ||
Line 751: | Line 593: | ||
| | | | ||
|- | |- | ||
| | |Somatostatinoma | ||
| | | | ||
| | | | ||
Line 763: | Line 605: | ||
| | | | ||
|- | |- | ||
| | |VIPoma | ||
| | | | ||
| | | | ||
Line 775: | Line 617: | ||
| | | | ||
|- | |- | ||
| | |ACTHoma | ||
| | | | ||
| | | | ||
Line 787: | Line 629: | ||
| | | | ||
|- | |- | ||
| | | rowspan="4" |Lung neuroendocrine tumors | ||
| | |Typical carcinoid tumours<ref name="pmid24213466">{{cite journal |vauthors=Fisseler-Eckhoff A, Demes M |title=Neuroendocrine tumors of the lung |journal=Cancers (Basel) |volume=4 |issue=3 |pages=777–98 |date=July 2012 |pmid=24213466 |pmc=3712715 |doi=10.3390/cancers4030777 |url=}}</ref><ref name="pmid27755793">{{cite journal |vauthors=Yang Z, Wang Z, Duan Y, Xu S |title=Clinicopathological characteristics and prognosis of resected cases of carcinoid tumors of the lung |journal=Thorac Cancer |volume=7 |issue=6 |pages=633–638 |date=November 2016 |pmid=27755793 |doi=10.1111/1759-7714.12377 |url=}}</ref><ref name="pmid26270444">{{cite journal |vauthors=Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ |title=Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience |journal=Am. J. Clin. Oncol. |volume=41 |issue=1 |pages=24–29 |date=January 2018 |pmid=26270444 |doi=10.1097/COC.0000000000000221 |url=}}</ref><ref name="pmid29770932">{{cite journal |vauthors=Papaxoinis G, Lamarca A, Quinn AM, Mansoor W, Nonaka D |title=Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations |journal=Endocr. Pathol. |volume= |issue= |pages= |date=May 2018 |pmid=29770932 |pmc=6097045 |doi=10.1007/s12022-018-9530-y |url=}}</ref> | ||
| | | | ||
* Asymptomatic | |||
* Constitutional | |||
* Cough | |||
* Hemoptysis | |||
* Recurrent pneumonia | |||
* Seizures | |||
| | | | ||
* ↓ Breath sounds | |||
* Fever | |||
* Weight loss | |||
* Carcinoid syndrome related | |||
* Cushing's syndrome related | |||
| | | | ||
* ↑ Urinary 5-hydroxyindole-acetic acid | |||
* ↑ Chromogranin A | |||
| | | | ||
* Central | |||
* Polypoid | |||
* Usually well defined | |||
* Smooth | |||
* No necrosis | |||
| | | | ||
* Organized structure | |||
* <2 mitoses/2 mm<sup>2</sup> | |||
* No necroses | |||
* Nesting and/or trabecular pattern | |||
| | | | ||
* Synaptophysin | |||
* Chromogranin A | |||
* CD56/NCAM | |||
* TTF1 | |||
* Estrogen receptor | |||
| | | | ||
* N/L | |||
* Coin lesion | |||
* Enlarged lymph nodes | |||
* Mass (rare) | |||
| | | | ||
* Bronchoscopy (Gold standard for tumor visualization) | |||
* Endoscopic biopsy | |||
| | | | ||
* N/A | |||
| | | | ||
* 5‐year survival rate >90% | |||
* 12% metastasis at presentation | |||
|- | |- | ||
| | |Atypical carcinoid tumours<ref name="pmid24213466" /><ref name="pmid27755793" /><ref name="pmid26270444" /><ref name="pmid29770932" /> | ||
| | | | ||
* Asymptomatic | |||
* Constitutional | |||
* Cough | |||
* Hemoptysis | |||
* Recurrent pneumonia | |||
* Seizures | |||
| | | | ||
* ↓ Breath sounds | |||
* Fever | |||
* Weight loss | |||
* Carcinoid syndrome related | |||
* Cushing's syndrome related | |||
| | | | ||
* ↑ Urinary 5-hydroxyindole-acetic acid | |||
* ↑ Chromogranin A | |||
| | | | ||
* Peripheral | |||
* Polypoid | |||
* Irregular margins | |||
* Smooth | |||
* Necrosis | |||
| | | | ||
* More pleomorphism | |||
* 2–10 mitoses/2 mm<sup>2</sup> | |||
* Necroses | |||
* Nesting and/or trabecular pattern | |||
| | | | ||
* Synaptophysin | |||
* Chromogranin A | |||
* CD56/NCAM | |||
* TTF1 | |||
* Estrogen receptor | |||
| | | | ||
* N/L | |||
* Coin lesion | |||
* Enlarged lymph nodes | |||
* Mass (rare) | |||
| | | | ||
* Bronchoscopy (Gold standard for tumor visualization) | |||
* Endoscopic biopsy | |||
| | | | ||
* N/A | |||
| | | | ||
* 5‐year survival rate 40-75% | |||
* 50% metastasis at presentation | |||
|- | |- | ||
| | |Large cell lung neuroendocrine carcinomas<ref name="pmid29114469">{{cite journal |vauthors=Hiroshima K, Mino-Kenudson M |title=Update on large cell neuroendocrine carcinoma |journal=Transl Lung Cancer Res |volume=6 |issue=5 |pages=530–539 |date=October 2017 |pmid=29114469 |pmc=5653527 |doi=10.21037/tlcr.2017.06.12 |url=}}</ref><ref name="pmid26039012">{{cite journal |vauthors=Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F |title=Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |journal=J Thorac Oncol |volume=10 |issue=8 |pages=1133–41 |date=August 2015 |pmid=26039012 |pmc=4503246 |doi=10.1097/JTO.0000000000000589 |url=}}</ref><ref name="pmid242134662">{{cite journal |vauthors=Fisseler-Eckhoff A, Demes M |title=Neuroendocrine tumors of the lung |journal=Cancers (Basel) |volume=4 |issue=3 |pages=777–98 |date=July 2012 |pmid=24213466 |pmc=3712715 |doi=10.3390/cancers4030777 |url=}}</ref><ref name="pmid25114839">{{cite journal |vauthors=Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T |title=Paraneoplastic syndromes associated with lung cancer |journal=World J Clin Oncol |volume=5 |issue=3 |pages=197–223 |date=August 2014 |pmid=25114839 |pmc=4127595 |doi=10.5306/wjco.v5.i3.197 |url=}}</ref> | ||
| | |||
| | |||
| | | | ||
* Asymptomatic | |||
* Cough | |||
* Hemoptysis | |||
* Recurrent infections | |||
* Seizures | |||
| | | | ||
* ↓ Breath sounds | |||
* Fever | |||
* Carcinoid syndrome related (rare) | |||
* Cushing's syndrome related (rare) | |||
| | | | ||
* ↑ Urinary 5-hydroxyindole-acetic acid (rare) | |||
* ↑ Serum ACTH (rare) | |||
* ↑ Chromogranin A | |||
| | | | ||
* Less differentiated | |||
* Grey-white | |||
* Invasive | |||
* Hemorrhage/necrosis | |||
| | | | ||
* Organoid or trabecular pattern | |||
* Rosette-like structures | |||
* Cells are ×3 the diameter of resting lymphocytes | |||
* Necrosis | |||
| | | | ||
* Chromogranin | |||
* Neuron-specific enolase | |||
* Synaptophysin | |||
* Somatostatin | |||
* CD56 | |||
| | | | ||
* Peripheral lesion | |||
* Expansively growing | |||
* Irregular margins | |||
* Mediastinal lymph node enlargement | |||
| | | | ||
* Bronchoscopy (Gold standard for tumor visualization) | |||
* SSTR (somatostatin receptors ) scintigraphy | |||
| | | | ||
* Biopsy with immunohisto-chemistry | |||
|Associated | |||
* Smoking | |||
* Humoral hypercalcemia of malignancy | |||
* SIADH | |||
* Hypoglycemia | |||
* Acromegaly | |||
* Carcinoid syndrome | |||
* Neurological syndromes | |||
* Gynecomastia | |||
* Hyperthyroidism | |||
|- | |- | ||
| | |Small cell lung neuroendocrine carcinomas<ref name="pmid291144692">{{cite journal |vauthors=Hiroshima K, Mino-Kenudson M |title=Update on large cell neuroendocrine carcinoma |journal=Transl Lung Cancer Res |volume=6 |issue=5 |pages=530–539 |date=October 2017 |pmid=29114469 |pmc=5653527 |doi=10.21037/tlcr.2017.06.12 |url=}}</ref><ref name="pmid260390122">{{cite journal |vauthors=Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F |title=Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |journal=J Thorac Oncol |volume=10 |issue=8 |pages=1133–41 |date=August 2015 |pmid=26039012 |pmc=4503246 |doi=10.1097/JTO.0000000000000589 |url=}}</ref><ref name="pmid242134663">{{cite journal |vauthors=Fisseler-Eckhoff A, Demes M |title=Neuroendocrine tumors of the lung |journal=Cancers (Basel) |volume=4 |issue=3 |pages=777–98 |date=July 2012 |pmid=24213466 |pmc=3712715 |doi=10.3390/cancers4030777 |url=}}</ref><ref name="pmid251148392">{{cite journal |vauthors=Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T |title=Paraneoplastic syndromes associated with lung cancer |journal=World J Clin Oncol |volume=5 |issue=3 |pages=197–223 |date=August 2014 |pmid=25114839 |pmc=4127595 |doi=10.5306/wjco.v5.i3.197 |url=}}</ref> | ||
| | |||
| | |||
| | | | ||
* Asymptomatic | |||
* Cough | |||
* Hemoptysis | |||
* Recurrent infections | |||
* Seizures | |||
| | | | ||
* ↓ Breath sounds | |||
* Fever | |||
* Carcinoid syndrome related (rare) | |||
* Cushing's syndrome related (rare) | |||
| | | | ||
* ↑ Urinary 5-hydroxyindole-acetic acid (rare) | |||
* ↑ Serum ACTH (rare) | |||
* ↑ Chromogranin A | |||
| | | | ||
* Less differentiated | |||
* Grey-white | |||
* Invasive | |||
* Hemorrhage/necrosis | |||
| | | | ||
* Diffuse sheets | |||
* No prominent neucleoli | |||
* Cells < size of three small resting lymphocytes | |||
* The mitotic rate averages over 60 mitoses/2 mm<sup>2</sup> | |||
* Extensive necrosis | |||
| | | | ||
* Chromogranin | |||
* Neuron-specific enolase | |||
* Synaptophysin | |||
* Somatostatin | |||
* CD56 | |||
| | | | ||
* Homogeneous or noncontiguous parenchymal mass, or peripheral nodule | |||
* Adjacent compression | |||
* Atelectasis | |||
* Pleural effusion . | |||
* Intratumoral calcification | |||
* Lymphadenopathy | |||
| | | | ||
* PET scan | |||
* Bronchoscopy | |||
* Scintigraphy | |||
| | | | ||
* Biopsy with immunohisto-chemistry | |||
|Associated | |||
* Smoking | |||
* Humoral hypercalcemia of malignancy | |||
* SIADH | |||
* Hypoglycemia | |||
* Acromegaly | |||
* Neurological syndromes | |||
* Gynecomastia | |||
* Hyperthyroidism | |||
|- | |||
| colspan="12" | | |||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 16:55, 24 January 2019
Neuroendocrine tumor | Clinical manifestations | Dianosis | Gold
standard |
Other features | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | Blood & Urine | Gross | Histology | Immunohistochemistry | Imaging | Others | ||||
Medullary thyroid carcinoma[1][2][3] |
|
|
|
|
|
|
|
|
chemistry and calcitonin levels |
| |
Pheochromocytoma[4][5][6][7][8] |
|
|
|
|
|
|
|
|
|
| |
Merkel cell carcinoma[9][10][11] |
|
|
|
|
|
|
|
|
|
| |
Parathyroid adenoma[12][13][14] |
|
|
|
|
|
|
|
Staining for
|
|
| |
Paraganglioma[15][16][17][18] |
|
|
|
|
|
|
|
|
N/A |
| |
Pituitary gland tumors | |||||||||||
Neuroendocrine tumors of the testicles[19][20][21] |
|
|
|
|
|
|
|
For metastasis and grading:
|
|
| |
Neuroendocrine tumors of the ovaries[22][23][24] |
|
|
|
|
|
|
|
For metastasis and grading:
|
|
| |
Thymic neuroendocrine cancer[25][26][27][28] |
|
|
|
|
|
|
|
For metastasis and grading:
|
|
| |
Jejuno-Ileal neuroendocrine tumors | |||||||||||
Appendix neuroendocrine tumors | |||||||||||
Colon neuroendocrine tumors | |||||||||||
Rectum neuroendocrine tumors | |||||||||||
Gastric neuroendocrine tumors | Type I GNET | ||||||||||
Type II GNET | |||||||||||
Type III GNET | |||||||||||
Type IV GNET | |||||||||||
Duodenal neuroendocrine tumors | Gastrinoma | ||||||||||
Somatostatinomas | |||||||||||
Gangliocytic paraganglionomas | |||||||||||
Nonfunctioning NET | |||||||||||
neuroendocrine carcinomas | |||||||||||
Pancreatic neuroendocrine tumours | Gastrinoma | ||||||||||
Insulinoma | |||||||||||
Glucagonoma | |||||||||||
Somatostatinoma | |||||||||||
VIPoma | |||||||||||
ACTHoma | |||||||||||
Lung neuroendocrine tumors | Typical carcinoid tumours[29][30][31][32] |
|
|
|
|
|
|
|
|
|
|
Atypical carcinoid tumours[29][30][31][32] |
|
|
|
|
|
|
|
|
|
| |
Large cell lung neuroendocrine carcinomas[33][34][35][36] |
|
|
|
|
|
|
|
|
|
Associated
| |
Small cell lung neuroendocrine carcinomas[37][38][39][40] |
|
|
|
|
|
|
|
|
|
Associated
| |
References
- ↑ Segura S, Ramos-Rivera G, Suhrland M (2018). "Educational Case: Endocrine Neoplasm: Medullary Thyroid Carcinoma". Acad Pathol. 5: 2374289518775722. doi:10.1177/2374289518775722. PMC 6024338. PMID 29978018.
- ↑ Roy M, Chen H, Sippel RS (2013). "Current understanding and management of medullary thyroid cancer". Oncologist. 18 (10): 1093–100. doi:10.1634/theoncologist.2013-0053. PMC 3805151. PMID 24037980.
- ↑ Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K (August 2010). "The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer". Pancreas. 39 (6): 775–83. doi:10.1097/MPA.0b013e3181ebb4f0. PMC 3419007. PMID 20664475.
- ↑ Martucci VL, Pacak K (2014). "Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment". Curr Probl Cancer. 38 (1): 7–41. doi:10.1016/j.currproblcancer.2014.01.001. PMC 3992879. PMID 24636754.
- ↑ Kantorovich V, Pacak K (2010). "Pheochromocytoma and paraganglioma". Prog. Brain Res. 182: 343–73. doi:10.1016/S0079-6123(10)82015-1. PMC 4714594. PMID 20541673.
- ↑ Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV (November 2009). "Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus)". Vet. Pathol. 46 (6): 1221–9. doi:10.1354/vp.09-VP-0022-M-FL. PMID 19605896.
- ↑ Kantorovich V, Eisenhofer G, Pacak K (December 2008). "Pheochromocytoma: an endocrine stress mimicking disorder". Ann. N. Y. Acad. Sci. 1148: 462–8. doi:10.1196/annals.1410.081. PMC 2693284. PMID 19120142.
- ↑ Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
- ↑ Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P (October 2017). "Merkel cell carcinoma". Nat Rev Dis Primers. 3: 17077. doi:10.1038/nrdp.2017.77. PMC 6054450. PMID 29072302.
- ↑ Han SY, North JP, Canavan T, Kim N, Yu SS (December 2012). "Merkel cell carcinoma". Hematol. Oncol. Clin. North Am. 26 (6): 1351–74. doi:10.1016/j.hoc.2012.08.007. PMID 23116583.
- ↑ Amaral T, Leiter U, Garbe C (December 2017). "Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy". Rev Endocr Metab Disord. 18 (4): 517–532. doi:10.1007/s11154-017-9433-0. PMID 28916903.
- ↑ Wieneke JA, Smith A (December 2008). "Parathyroid adenoma". Head Neck Pathol. 2 (4): 305–8. doi:10.1007/s12105-008-0088-8. PMID 20614300.
- ↑ Madkhali T, Alhefdhi A, Chen H, Elfenbein D (2016). "Primary hyperparathyroidism". Ulus Cerrahi Derg. 32 (1): 58–66. doi:10.5152/UCD.2015.3032. PMC 4771429. PMID 26985167.
- ↑ Costa-Guda J, Arnold A (April 2014). "Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors". Mol. Cell. Endocrinol. 386 (1–2): 46–54. doi:10.1016/j.mce.2013.09.005. PMC 3943641. PMID 24035866.
- ↑ Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
- ↑ Baez JC, Jagannathan JP, Krajewski K, O'Regan K, Zukotynski K, Kulke M, Ramaiya NH (May 2012). "Pheochromocytoma and paraganglioma: imaging characteristics". Cancer Imaging. 12: 153–62. doi:10.1102/1470-7330.2012.0016. PMC 3362869. PMID 22571874.
- ↑ Liu YQ, Yue JQ (2013). "Paraganglioma of the vulva: a case report and review of the literature". Int J Clin Exp Pathol. 6 (10): 2247–50. PMC 3796250. PMID 24133606.
- ↑ Wang ZH, Wang YT, Cheng F, Hu Y (October 2018). "Pathological features of paraganglioma in the lumbar spinal canal: A case report". Medicine (Baltimore). 97 (41): e12586. doi:10.1097/MD.0000000000012586. PMC 6203573. PMID 30313044.
- ↑ Amine MM, Mohamed B, Mourad H, Majed H, Slim C, Mehdi B, Hela M, Nouri R, Rim K, Tahya B, Nabil MM (April 2017). "Neuroendocrine Testicular Tumors: A Systematic Review and Meta-Analysis". Curr Urol. 10 (1): 15–25. doi:10.1159/000447146. PMC 5436018. PMID 28559773.
- ↑ Park SB, Kim JK, Cho KS (March 2006). "Imaging findings of a primary bilateral testicular carcinoid tumor associated with carcinoid syndrome". J Ultrasound Med. 25 (3): 413–6. PMID 16495507.
- ↑ Eichhorn JH, Young RH (June 2001). "Neuroendocrine tumors of the genital tract". Am. J. Clin. Pathol. 115 Suppl: S94–112. doi:10.1309/64CW-WKGK-49EF-BYD1. PMID 11993694.
- ↑ Orsi NM, Menon M (August 2016). "Primary ovarian neuroendocrine tumor arising in association with a mature cystic teratoma: A case report". Gynecol Oncol Rep. 17: 83–5. doi:10.1016/j.gore.2016.07.003. PMC 4971231. PMID 27508272.
- ↑ Kaiho-Sakuma M, Toyoshima M, Watanabe M, Toki A, Kameda S, Minato T, Niikura H, Yaegashi N (February 2018). "Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report". Gynecol Oncol Rep. 23: 20–23. doi:10.1016/j.gore.2018.01.002. PMC 5760241. PMID 29326972.
- ↑ Eichhorn JH, Young RH (June 2001). "Neuroendocrine tumors of the genital tract". Am. J. Clin. Pathol. 115 Suppl: S94–112. doi:10.1309/64CW-WKGK-49EF-BYD1. PMID 11993694.
- ↑ Bohnenberger H, Dinter H, König A, Ströbel P (November 2017). "Neuroendocrine tumors of the thymus and mediastinum". J Thorac Dis. 9 (Suppl 15): S1448–S1457. doi:10.21037/jtd.2017.02.02. PMC 5690954. PMID 29201448.
- ↑ Moran CA, Suster S (July 2000). "Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases". Am. J. Clin. Pathol. 114 (1): 100–10. doi:10.1309/3PDN-PMT5-EQTM-H0CD. PMID 10884805.
- ↑ Boubacar E, Atsame-Ebang G, Rabiou S, Fatimazahra A, Mazti A, Sidibé IS, Tahiri L, Hammas N, Yassine O, Mohamed S, Laila C, Hinde EF (June 2017). "Thymic large cell neuroendocrine carcinoma - a rare and aggressive tumor: a case report". J Med Case Rep. 11 (1): 155. doi:10.1186/s13256-017-1331-2. PMC 5467048. PMID 28602157.
- ↑ Domen H, Hida Y, Sato M, Takahashi H, Ishikawa T, Shionoya Y, Hashimoto M, Nishiyama K, Aoki Y, Inoko K, Furukawa S, Ichinokawa K, Yamada H (November 2018). "Resected thymic large cell neuroendocrine carcinoma: report of a case". Surg Case Rep. 4 (1): 133. doi:10.1186/s40792-018-0540-2. PMC 6240022. PMID 30446840.
- ↑ 29.0 29.1 Fisseler-Eckhoff A, Demes M (July 2012). "Neuroendocrine tumors of the lung". Cancers (Basel). 4 (3): 777–98. doi:10.3390/cancers4030777. PMC 3712715. PMID 24213466.
- ↑ 30.0 30.1 Yang Z, Wang Z, Duan Y, Xu S (November 2016). "Clinicopathological characteristics and prognosis of resected cases of carcinoid tumors of the lung". Thorac Cancer. 7 (6): 633–638. doi:10.1111/1759-7714.12377. PMID 27755793.
- ↑ 31.0 31.1 Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (January 2018). "Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience". Am. J. Clin. Oncol. 41 (1): 24–29. doi:10.1097/COC.0000000000000221. PMID 26270444.
- ↑ 32.0 32.1 Papaxoinis G, Lamarca A, Quinn AM, Mansoor W, Nonaka D (May 2018). "Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations". Endocr. Pathol. doi:10.1007/s12022-018-9530-y. PMC 6097045. PMID 29770932.
- ↑ Hiroshima K, Mino-Kenudson M (October 2017). "Update on large cell neuroendocrine carcinoma". Transl Lung Cancer Res. 6 (5): 530–539. doi:10.21037/tlcr.2017.06.12. PMC 5653527. PMID 29114469.
- ↑ Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F (August 2015). "Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy". J Thorac Oncol. 10 (8): 1133–41. doi:10.1097/JTO.0000000000000589. PMC 4503246. PMID 26039012.
- ↑ Fisseler-Eckhoff A, Demes M (July 2012). "Neuroendocrine tumors of the lung". Cancers (Basel). 4 (3): 777–98. doi:10.3390/cancers4030777. PMC 3712715. PMID 24213466.
- ↑ Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (August 2014). "Paraneoplastic syndromes associated with lung cancer". World J Clin Oncol. 5 (3): 197–223. doi:10.5306/wjco.v5.i3.197. PMC 4127595. PMID 25114839.
- ↑ Hiroshima K, Mino-Kenudson M (October 2017). "Update on large cell neuroendocrine carcinoma". Transl Lung Cancer Res. 6 (5): 530–539. doi:10.21037/tlcr.2017.06.12. PMC 5653527. PMID 29114469.
- ↑ Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F (August 2015). "Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy". J Thorac Oncol. 10 (8): 1133–41. doi:10.1097/JTO.0000000000000589. PMC 4503246. PMID 26039012.
- ↑ Fisseler-Eckhoff A, Demes M (July 2012). "Neuroendocrine tumors of the lung". Cancers (Basel). 4 (3): 777–98. doi:10.3390/cancers4030777. PMC 3712715. PMID 24213466.
- ↑ Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (August 2014). "Paraneoplastic syndromes associated with lung cancer". World J Clin Oncol. 5 (3): 197–223. doi:10.5306/wjco.v5.i3.197. PMC 4127595. PMID 25114839.